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Abstract  This  article  reviews  the  major  pharmacologic  features  of,  and  clinical  evidence  on,
adjuvant medical  therapy  in  patients  with  ST-elevation  myocardial  infarction  (STEMI)  treated
with primary  percutaneous  coronary  intervention.  These  drugs  include  oral  antiplatelets  (aspirin
and P2Y12 inhibitors  such  as  clopidogrel,  prasugrel  and  ticagrelor),  intravenous  antiplatelet
agents  (the  P2Y12 inhibitor  cangrelor,  GP  IIb/IIIa  inhibitors  such  as  abciximab,  eptiﬁbatide  and
tiroﬁban),  and  intravenous  anticoagulant  agents  (unfractionated  heparin,  low  molecular  weight
heparin and  bivalirudin).
© 2019  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  All  rights
reserved.
PALAVRAS-CHAVE
Enfarte  do  miocárdio;
Antiagregante;
Anticoagulante;
Antitrombótico;
Adjuvante
Terapêutica  antitrombótica  adjuvante  no  enfarte  do  miocárdio
com  supra-desnivelamento  do  segmento  ST:  revisão  narrativa
Resumo  Neste  artigo  foram  analisadas  as  principais  características  farmacológicas  e  a  evidên-
cia clínica  do  uso  de  terapêutica  médica  adjuvante  em  doentes  com  enfarte  do  miocárdio
com supradesnivelamento  do  segmento  ST  tratados  com  angioplastia  primária.  Esses  fármacos
incluem antiagregantes  orais  (ácido  acetilsalicílico  e  inibidores  de  P2Y12,  tais  como  clopidogrel,
prasugrel,  ticagrelor),  antiagregantes  endovenosos  (o  inibidor  P2Y12  cangrelor,  inibidores  GpI-tiﬁbatide  e  tiroﬁban)  e  agentes  anticoagulantes  de  uso  endovenoso
eparina  de  baixo  peso  molecular  e  bivalirudina).
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ntroduction
he  acute  standard  of  care  for  ST-elevation  myocardial
nfarction  (STEMI)1--3 includes  activation  of  a  STEMI  care
etwork,  administration  of  adjuvant  medical  therapy,  and
eperfusion  by  primary  percutaneous  coronary  intervention
PCI).
Developments  in  organizational  aspects  of  health  care,
uch  as  the  Stent  for  Life  initiative,  and  in  reperfusion  ther-
py,  have  established  primary  PCI  as  the  current  ﬁrst  option
or  the  treatment  of  patients  with  STEMI,  due  to  its  impact
n  prognosis.4,5
The  improvements  now  seen  in  STEMI  care  are  closely
elated  to  advances  in  adjuvant  medical  therapy  in  recent
ecades,  particularly  antithrombotic  therapy.
In  this  article,  we  present  a  narrative  review  describing
he  main  pharmacologic  characteristics  of,  and  clinical  evi-
ence  on,  adjuvant  medical  therapy  used  in  the  acute  phase
f  STEMI.
eview
spirin  (Acetylsalicylic  Acid)
spirin  acts  as  a  platelet  inhibitor  at  lower  doses  (75-
25  mg),  but  has  antipyretic  and  anti-inﬂammatory  effects
t  higher  doses.
The  landmark  trial  for  antiplatelet  treatment  in  patients
ith  acute  myocardial  infarction  (MI)  was  the  1988  Second
nternational  Study  of  Infarct  Survival  (ISIS-2).6
In  this  trial,  the  administration  of  162.5  mg  aspirin  for
0  days  achieved  a  21%  relative  risk  reduction  (RRR)  in  vas-
ular  mortality  compared  with  placebo  (Figure  1),  which
as  similar  to  the  effect  of  streptokinase  alone  (RRR  23%).
 reduction  of  39%  in  vascular  mortality  was  observed  when
spirin  was  added  to  streptokinase.6 Overall,  aspirin  treat-
ent  showed  an  absolute  risk  reduction  in  vascular  mortality
f  2.4%  and  a  number  needed  to  treat  of  42  patients  within
ve  weeks  to  prevent  one  vascular  death,  compared  with
lacebo.
During  the  acute  presentation  of  STEMI,  the  guidelines
ecommend  a  loading  dose  of  aspirin  of  150-300  mg  orally  or
0-150  mg  intravenously  with  lysine  acetylsalicylate  in  order
o  ensure  inhibition  of  serum  thromboxane  B2  synthesis.1,3,7
The  issue  of  aspirin  dosing  was  further  analyzed  in  the
lopidogrel  and  Aspirin  Optimal  Dose  Usage  to  Reduce
ecurrent  Events−Seventh  Organization  to  Assess  Strategies
n  Ischemic  Syndromes  7  (CURRENT-OASIS  7)  trial,  which
ncluded  25  086  patients  with  acute  coronary  syndromes
29%  of  whom,  about  7000  patients,  presented  with  STEMI).8
atients  randomized  to  high-dose  aspirin  (300-325  mg  daily)
or  seven  days  showed  similar  rates  to  the  low-dose  group
75-100  mg  daily)  for  the  composite  outcome  of  30-day  car-
iovascular  mortality,  non-fatal  MI  or  non-fatal  stroke.  The
econdary  outcomes  were  also  similar  between  the  interven-
ions,  with  the  exception  of  a  lower  incidence  of  recurrent
schemia  in  the  high-dose  aspirin  arm.  Minor  bleeding  events
ere  increased  with  high-dose  aspirin  but  the  risk  of  major
leeding  was  similar  with  the  different  doses.8
p
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2Y12 inhibitors:  clopidogrel,  prasugrel,  ticagrelor
nd cangrelor
lopidogrel
he  beneﬁts  of  the  addition  of  a  second  antiplatelet  agent
n  addition  to  aspirin  in  STEMI  patients  are  clearly  demon-
trated  by  clopidogrel.  Clopidogrel  is  a  second-generation
ember  of  the  thienopyridine  drug  class,  which  inhibit  bind-
ng  of  ADP  to  P2Y12 receptors  in  platelets  and  thus  prevent
DP-related  glycoprotein  (GP)  IIb/IIIa  receptor  activation.
Clopidogrel  is  a prodrug  and  requires  a  two-step  acti-
ation  process  in  the  liver  in  which  it  is  converted  by
ytochrome  P450  (CYP)  enzymes  into  an  intermediate
etabolite  and  a  ﬁnal  active  metabolite.  CYP2C19  is
ne  of  the  most  important  CYPs  involved  in  clopidogrel
etabolism.  The  concomitant  use  of  CYP2C19  inhibitors
omeprazole,  ﬂuoxetine,  or  azole  antifungal  agents)  leads
o  decreased  levels  of  the  active  metabolite,  but  the  clinical
elevance  of  this  decrease  has  not  been  clearly  determined.9
hus,  alternative  drugs  should  be  considered  before  pre-
cribing  CYP2C19  inhibitors.
Clopidogrel  as  Adjunctive  Reperfusion  Therapy  -  Throm-
olysis  In  Myocardial  Infarction  (CLARITY-TIMI  28)  was  a
lacebo-controlled  trial  designed  to  determine  whether
lopidogrel  added  to  standard  antiplatelet  therapy  with
spirin  (loading  dose  plus  maintenance  dose  of  75-
62  mg/day)  would  further  improve  the  prognosis  of  adult
atients  (18-75  years  old)  managed  with  ﬁbrinolysis.10
 total  of  3491  patients  presenting  within  12  hours  of
I  intended  for  treatment  with  a  ﬁbrinolytic  agent  were
nrolled  and  randomized  to  receive  either  aspirin  alone  or
spirin  plus  clopidogrel  (300  mg  loading  dose  followed  by  75
g/day).  The  addition  of  clopidogrel  to  aspirin  showed  an
RR  of  36%  for  occluded  infarct-related  artery,  death  or  MI
y  the  time  of  angiography,  and  a  20%  RRR  for  cardiovascu-
ar  mortality,  MI  or  urgent  revascularization  due  to  recurrent
schemia  at  30  days.10
The  PCI-CLARITY  study  was  a  subgroup  analysis  of
LARITY-TIMI  28,  with  1863  patients  undergoing  PCI  a  median
f  three  days  after  randomization.  All  patients  in  this  sub-
roup  received  a  loading  dose  of  300  mg,  then  75  mg
nce  daily  of  open-label  clopidogrel  before  PCI.  Pretreat-
ent  with  clopidogrel  after  ﬁbrinolytic  therapy  and  before
CI  resulted  in  a  46%  RRR  of  the  composite  of  cardiovas-
ular  death,  recurrent  MI  or  stroke  compared  to  placebo
Figure  1).11
The  clopidogrel  arm  of  ClOpidogrel  and  Metoprolol  in
yocardial  Infarction  Trial/Second  Chinese  Cardiac  Study
COMMIT-CCS2)12 enrolled  45  852  patients  with  MI  (93%  with
TEMI  or  MI  with  left  bundle  branch  block)  randomized  to
eceive  either  clopidogrel  or  placebo  in  addition  to  aspirin
62  mg/daily  until  discharge  or  up  to  four  weeks  in  hospital.
lopidogrel  signiﬁcantly  reduced  all-cause  mortality  and  the
omposite  outcome  of  death,  reinfarction  or  stroke,  with
RRs  of  7%  and  9%,  respectively,  after  a  mean  treatment
eriod  of  two  weeks.
The  rates  of  major  bleeding  found  in  these  two  trials
CLARITY-TIMI  28  and  COMMIT-CCS2)  were  not  signiﬁcantly
ncreased.10,12
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Estimate (RR/OR/HR) Estimate (RR/OR/HR)
95% CI 95% CI
Aspirin
ISIS-2(1)
P2Y12  inhibitors
PCI-CLARITY (2)
TRITON-TIMI 38 (STEMI subgroup) (3)
PLATO (STEMI subgroup ) (4)
CHAMPION PHOENIX(STEMI subgroup) (5)
GP IIb/IIIa inhibitors
De Luca et al. [meta-analysis] (6)
On-TIME 2 (7)
EVA-AMI (8)
(1) Aspirin vs. placebo; 1-month cardiovascular mortality
(2) Clopidogrel vs. placebo; 1-month CV death, MI or stroke 
(3) Prasugrel vs. clopidorel; CV death, MI or stroke
(4) Ticagrelor vs. clopidogrel; CV death, MI or stroke
(5) Cangrelor vs. placebo; death, MI, ischemic-driven revascularization or stent thrombosis
(6) Abciximab vs. control; 6 month-1 year mortality
(7) Tirofiban vs. placebo; thrombotic bail-out (secondary outcome)
(8) Eptifibatide vs. abciximab; death, MI or TVR (secondary outcome)
0.79 [0.73, 0.86]
0.54 [0.35, 0.85]
0.79 [0.64, 0.97]
0.87 [0.75, 1.01]
0.75 [0.45, 1.25]
0.69 [0.52, 0.92]
0.70 [0.56, 0.88]
0.93 [0.54, 1.59]
0.5
Favors intervention Favors control
 0.7 1 1.5 2
Figure  1  Results  of  selected  trials  assessing  antiplatelet  agents  in  patients  with  ST-segment  elevation  myocardial  infarction.  CI:
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Clopidogrel  loading  doses  (600  mg  vs.  300  mg)  were
compared  in  201  STEMI  patients  undergoing  primary  PCI  in
the  Antiplatelet  therapy  for  Reduction  of  MYocardial  Dam-
age  during  Angioplasty-Myocardial  Infarction  (ARMYDA-6  MI)
trial.13 The  primary  outcome,  the  area  under  the  curve
of  cardiac  biomarkers  as  a  surrogate  of  myocardial  infarct
size,  was  signiﬁcantly  lower  with  the  600  mg  loading  dose
than  with  the  300  mg  loading  dose.  There  were  also  fewer
30-day  major  adverse  cardiovascular  events  but  bleeding
complications  were  similar  between  the  different  loading
doses.13
The  CURRENT-OASIS  7  trial  (see  section  on  aspirin,
above),  with  a  2-by-2  factorial  design,  also  assessed  the  clin-
ical  impact  of  high-dose  clopidogrel  (loading  dose  600  mg,
six  days  at  150  mg/day,  followed  by  75  mg/day)  vs.  stan-
dard  dose  (loading  dose  300  mg,  followed  by  75  mg/day).8
Overall,  high-dose  clopidogrel  did  not  reduce  30-day  car-
diovascular  mortality,  MI  or  stroke,  but  in  the  subgroup  of
patients  who  underwent  PCI  (STEMI  and  non-STEMI)  the  risk
of  these  major  adverse  cardiovascular  events  was  signiﬁcan-
tly  decreased,  mainly  due  to  the  reduction  of  MI.  High-dose
clopidogrel  increased  the  risk  of  major  bleeding.8
Prasugrel
Prasugrel,  another  member  of  the  thienopyridine  drug  class,
is  an  irreversible  P2Y12 inhibitor  that  overcomes  some
of  clopidogrel’s  limitations,  particularly  the  degree  of  its
antiplatelet  effect  and  time  to  onset.
Prasugrel  is  rapidly  hydrolyzed  to  a  thiolactone  in  the
intestine,  and  then  after  absorption  is  converted  by  CYP3A4
and  CYP2B6  and  to  a  lesser  extent  by  CYP2C9  and  CYP2C19  to
the  active  metabolite,  which  reaches  peak  plasma  concen-
tration  30  min  after  administration.
The  beneﬁts  of  prasugrel  (loading  dose  60  mg,  followed
by  10  mg  once  daily)  instead  of  clopidogrel  in  addition  to
a
od  ratio;  MI:  myocardial  infarction;  OR:  odds  ratio;  RR:  relative
t  vessel  revascularization.
spirin  (at  any  dose  from  75  to  162  mg)  were  shown  by  the
RITON-TIMI  38  trial,  which  enrolled  13  608  patients  with
cute  coronary  syndromes  managed  invasively  with  PCI.14
Prasugrel  reduced  the  relative  risk  of  the  composite  out-
ome  of  cardiovascular  death,  non-fatal  MI  and  non-fatal
troke  by  19%  compared  with  clopidogrel.  The  results  were
ainly  driven  by  reduced  risk  for  non-fatal  MI  (RRR  24%),
nd  the  overall  clinical  impact  of  prasugrel  was  not  differ-
nt  within  the  subgroup  of  3534  STEMI  patients  (p=NS  for
nteraction);  the  RRR  in  this  subgroup  was  21%.  There  was
o  mortality  beneﬁt  with  prasugrel  and  the  bleeding  risk
as  signiﬁcantly  higher  according  to  the  study  deﬁnition  of
ajor  bleeding  (TIMI  major  bleeding  not  related  to  coronary
rtery  bypass  grafting  [CABG]).14 The  risk  of  death,  non-
atal  MI,  non-fatal  stroke  and  non-CABG-related  TIMI  major
leeding  was  signiﬁcantly  higher  in  patients  with  a  history
f  stroke  or  transient  ischemic  attack,  and  thus  prasugrel  is
ot  indicated  for  these  patients.  Other  subgroups  for  which
peciﬁc  concerns  were  raised  were  the  elderly  (≥75  years
ld)  and  low-weight  individuals  (<60  kg),  particularly  regard-
ng  their  bleeding  risk  with  10  mg  prasugrel  daily.  Current
egulatory  documents  recommend  a  careful  individual  ben-
ﬁt/risk  assessment  and  if  prescribed  the  maintenance  dose
hould  be  5  mg  daily  for  such  patients.
icagrelor
icagrelor  is  an  oral  cyclopentyltriazolopyrimidine  that
eversibly  and  non-competitively  inhibits  ADP-induced  sig-
aling  downstream  of  P2Y12 receptors.  Compared  to
lopidogrel,  ticagrelor  showed  a  favorable  proﬁle  regarding
ime  to  onset  and  degree  of  antiplatelet  effect.Ticagrelor  reaches  peak  plasma  levels  between  90  min
nd  three  hours  and  peak  platelet  inhibition  in  two  hours.
The  pivotal  trial  of  ticagrelor  in  ACS  was  PLATO  (a  Study
f  PLATelet  Inhibition  and  Patient  Outcomes),  in  which  dual
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ntiplatelet  treatment  with  aspirin  and  ticagrelor  was  com-
ared  with  aspirin  and  clopidogrel.  The  trial  included  a  total
f  18  624  patients  with  ACS.  Both  P2Y12 inhibitors  were  given
n  a  loading  dose  (ticagrelor  180  mg;  clopidogrel  300-600  mg)
nd  a  maintenance  dose  (ticagrelor  90  mg  twice  daily;  clopi-
ogrel  75  mg  once  daily).  Ticagrelor  showed  a  signiﬁcant
6%  RRR  in  cardiovascular  mortality,  MI  and  stroke,  due  to
ecreases  in  cardiovascular  mortality  and  MI.  Overall  major
leeding  risk  was  not  signiﬁcantly  increased,  but  non-CABG-
elated  major  bleeding  was  signiﬁcantly  increased.
This  trial  included  7544  patients  with  STEMI,  and  the
ubgroup’s  result  was  similar  to  the  non-STEMI  population
p=0.29  for  interaction).  It  is  noteworthy  that  ticagrelor  had
ess  effect  in  North  America  than  in  the  rest  of  the  world.15
ther  than  chance  alone  or  a  true  regional  difference,  one
ossible  explanation  is  the  fact  that  the  aspirin  maintenance
ose  was  on  average  higher  in  North  America.  A  signiﬁcant
tatistical  interaction  was  observed  favoring  the  interaction
f  low-dose  aspirin  with  ticagrelor.  The  recommended  dose
f  aspirin  to  be  taken  with  ticagrelor  is  75-150  mg,  prefer-
bly  lower  doses.
The  main  adverse  events  associated  with  ticagrelor  are
yspnea  and  bradyarrhythmias.  The  incidence  of  dyspnea
n  the  ticagrelor  arm  in  the  PLATO  trial  was  13.8%.  It  was
sually  non-severe,  transient  and  not  related  to  cardiac,
ulmonary  or  metabolic  factors.
Ventricular  pauses  of  >3  s,  assessed  by  Holter  monitoring,
ere  more  frequent  with  ticagrelor  than  with  clopidogrel
n  the  acute  phase  of  the  coronary  event  (during  the  ﬁrst
eek),  but  not  at  30  days  after  randomization.  The  risk
f  heart  block,  syncope  and  pacemaker  implantation  with
icagrelor  was  not  signiﬁcantly  different  from  clopidogrel.
In  addition  to  P2Y12 signal  blockade,  ticagrelor  also
nhibits  equilibrative  nucleoside  transporter-1  (ENT-1),
hich  is  implicated  in  the  cellular  uptake  of  endogenous
denosine.16--18 The  above  adverse  drug  reactions  may  be
elated  to  this  mechanism.
The  Administration  of  Ticagrelor  in  the  Cath  Lab  or
n  the  Ambulance  for  New  ST  Elevation  Myocardial  Infarc-
ion  to  Open  the  Coronary  Artery  (ATLANTIC)  trial  assessed
he  potential  beneﬁts  of  the  prehospital  administration
f  ticagrelor  compared  with  in-hospital  administration.19
n  this  study  involving  1862  STEMI  patients,  the  median
ime  from  randomization  to  coronary  angiogram  was  48  min
nd  the  median  time  difference  between  pre-hospital  and
n-hospital  administration  of  the  ticagrelor  loading  dose  was
1  min.  The  primary  outcomes,  surrogates  of  antithrombotic
fﬁcacy  related  to  pre-PCI  coronary  reperfusion  (resolution
f  ST-segment  elevation  and  the  proportion  of  coronary  TIMI
ow  <3),  were  not  improved  by  early  pre-hospital  ticagrelor
dministration.  The  risk  of  deﬁnite  stent  thrombosis  was
ower  with  pre-hospital  ticagrelor  administration.19
angrelor
angrelor  is  an  intravenous  reversible  P2Y12 inhibitor.  The
ain  advantages  of  this  drug  are  rapid  onset  (within  2  min
f  a  bolus  followed  by  an  infusion)  and  offset  (one  hour  after
topping  drug  infusion)  of  antiplatelet  effects.20
The  drug  is  metabolized  in  the  plasma  into  an  inactive
etabolite  which  is  eliminated  through  renal  and  digestive
T
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outes.  Thus,  cangrelor  does  not  require  dose  adjustments
n  renal  or  liver  impairment.
Cangrelor  has  been  approved  for  patients  with  coronary
isease  undergoing  PCI  who  did  not  receive  an  oral  P2Y12
nhibitor  prior  to  the  procedure  and  in  whom  current  oral
herapy  with  P2Y12 inhibitors  is  not  feasible  (e.g.  absence  of
ral  route)  or  desirable  (e.g.  bridging  to  CABG  surgery).20
The  pivotal  CHAMPION  PHOENIX  (Cangrelor  versus  Stan-
ard  Therapy  to  Achieve  Optimal  Management  of  Platelet
nhibition  PHOENIX)  trial  compared  cangrelor  and  placebo
n  10  942  patients  treated  with  a  300-  or  600-mg  loading
ose  of  clopidogrel  before  PCI.21 This  trial  showed  an  RRR
f  22%  and  15%  in  the  composite  endpoint  of  mortality  and
schemic  events  (MI,  ischemia-driven  revascularization  or
tent  thrombosis)  at  48  hours  and  30  days  of  follow-up,
espectively.  This  beneﬁt  was  mainly  driven  by  a  signiﬁ-
ant  RRR  of  38%  in  stent  thrombosis  (intraprocedural  stent
hrombosis  independently  adjudicated  by  the  angiographic
ore  laboratory  committee,  or  deﬁnite  stent  thrombosis  as
eﬁned  by  the  Academic  Research  Consortium  criteria22).
HAMPION  PHOENIX  included  1992  patients  with  STEMI  and
o  interaction  was  observed  regarding  treatment  effect
ccording  to  clinical  presentation  (STEMI  and  non-STEMI).21
The  beneﬁts  of  cangrelor  are  likely  related  to  its  rapid
ntiplatelet  action  compared  to  other  oral  P2Y12 inhibitors
uch  as  clopidogrel.
lycoprotein  IIb/IIIa  inhibitors
his  class  includes  three  drugs,  administered  intravenously,
hat  disable  ﬁbrinogen  and  von  Willebrand  factor  by  binding
o  the  GP  IIb/IIIa  receptor:  abciximab,  tiroﬁban  and  eptiﬁ-
atide.
bciximab
bciximab  is  an  antigen-binding  fragment  of  a chimeric  mon-
clonal  antibody  that  binds  to  GP  IIb/IIIa  and  vitronectin
eceptors.  Abciximab’s  antiplatelet  effect  is  seen  10  min
fter  bolus  administration  and  platelet  function  typically
ecovers  24-48  hours  after  drug  withdrawal.23--25
Most  of  the  evidence  supporting  the  use  of  GP  IIb/IIIa
nhibitors  in  STEMI  arises  from  trials  with  abciximab  in  the
ra  of  balloon  angioplasty  and  before  the  routine  implemen-
ation  of  dual  antiplatelet  therapy  in  these  patients.  De  Luca
t  al.  published  a  systematic  review  on  the  clinical  impact
f  abciximab  in  STEMI  patients  treated  with  ﬁbrinolysis  or
rimary  PCI.26 In  this  review  abciximab  reduced  both  30-day
nd  long-term  (six  months  to  one  year)  all-cause  mortality  by
1%  and  32%,  respectively.  No  signiﬁcant  increase  in  major
leeding  risks,  including  intracranial  hemorrhage,  was  noted
Figure  1).26
The  main  adverse  event  rather  than  bleeding  (major  or
inor)  is  thrombocytopenia,  which  usually  develops  in  the
rst  24  hours.  The  incidence  of  thrombocytopenia  is  2.9%  for
rst  administration  and  5%  for  repeat  administrations.27,28iroﬁban
iroﬁban  is  a  non-competitive  non-peptide  GP  IIb/IIIa  recep-
or  antagonist.  This  drug’s  antiplatelet  effect  begins  15  min
fter  a  bolus  administration  of  0.25  g/kg,29 and  inhibition
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of  platelet  aggregation  is  <50%  four  hours  after  cessation  of
drug  infusion.30
In  the  On-TIME  2  trial,  936  STEMI  patients  were  random-
ized  to  high-dose  tiroﬁban  or  placebo  in  the  pre-hospital
setting,  on  top  of  aspirin  500  mg,  clopidogrel  600  mg,  and
unfractionated  heparin  5000  IU.31 The  trial  was  designed
to  assess  ST-elevation  resolution,  and  tiroﬁban  signiﬁcan-
tly  decreased  the  extent  of  residual  ST-segment  deviation
one  hour  after  PCI.  The  rates  of  the  composite  of
death,  recurrent  MI  or  target  vessel  revascularization,  and
major  bleeding  were  not  signiﬁcantly  different  between
interventions.  There  was  signiﬁcantly  less  need  for  throm-
botic  bail-out  due  to  TIMI  ﬂow  grade  0-2  and  abrupt  closure
of  the  culprit  vessel  in  the  tiroﬁban  arm  (Figure  1).  In-
hospital  thrombocytopenia  was  not  signiﬁcantly  higher  (2.0%
with  tiroﬁban  and  1.8%  with  placebo).
Eptiﬁbatide
Eptiﬁbatide  is  a  synthetic  heptapeptide  that  reversibly
and  competitively  inhibits  GP  IIb/IIIa  receptors.  It  is  given
through  an  initial  double  intravenous  bolus  (separated  by
10  min)  of  180  g/kg  followed  by  a  continuous  infusion  of
2  g/kg/min  for  up  to  72  hours.  The  antiplatelet  effects
are  observed  after  the  bolus  and  platelet  function  recovers
four  hours  after  cessation  of  infusion.  Because  50%  of  epti-
ﬁbatide  clearance  is  kidney-dependent,  the  infusion  dose
should  be  halved  in  patients  with  moderate  chronic  kidney
disease  (estimated  glomerular  ﬁltration  rate  30-50  ml/min).
The  main  data  on  eptiﬁbatide  use  in  acute  coronary  syn-
dromes  come  from  the  PURSUIT  trial,  which  enrolled  only
patients  without  persistent  ST-segment  elevation.32 PUR-
SUIT  was  a  randomized,  double-blind  assessment  of  the
efﬁcacy  and  safety  of  eptiﬁbatide  versus  placebo  for  redu-
cing  mortality  and  MI  in  patients  with  unstable  angina  or
non-Q-wave  MI  and  included  13.8%  of  patients  with  non-
persistent  ST  segment  elevation  or  persistent  ST-segment
elevation  of  0.5-0.9  mm.  This  trial  showed  a  RRR  of  10%  in
mortality  or  MI  at  30  days.  A  signiﬁcant  increase  in  major
and/or  minor  bleeding  events  was  observed  in  the  eptiﬁ-
batide  arm.  The  risk  of  thrombocytopenia  with  eptiﬁbatide
was  not  signiﬁcantly  different  from  placebo.
In  the  context  of  STEMI,  the  Eptiﬁbatide  Versus  Abciximab
in  Primary  PCI  for  Acute  Myocardial  Infarction  (EVA-AMI)
trial  randomized  427  STEMI  patients  to  eptiﬁbatide  (double
bolus  and  24-hour  infusion)  or  abciximab  (bolus  and  12-hour
infusion)  as  adjuncts  to  primary  PCI.33 The  primary  out-
come  was  complete  ST-segment  resolution  60  min  after  PCI.
The  electrocardiographic  and  clinical  impact  of  eptiﬁbatide
was  similar  to  abciximab  (Figure  1).  Non-randomized  studies
show  similar  ﬁndings.34,35
Heparins
Unfractionated  heparin
Unfractionated  heparin  (UFH)  is  a  polysaccharide  that  binds
to  plasma  proteins,  including  antithrombin,  enhancing  its
action,  which  includes  inactivation  of  thrombin  and  factor
Xa.  The  heparin-antithrombin  complex  also  inhibits  other
coagulation  factors  including  VIIa,  XIa  and  XIIa.  UFH  also
enhances  endogenous  ﬁbrinolysis.  UFH  is  usually  given  intra-
venously,  including  in  the  context  of  STEMI.
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This  drug  has  two  independent  clearance  mechanisms:
 saturable  pathway  in  which  rapid  depolymerization  fol-
ows  binding  to  endothelial  cells,  macrophages  and  local
roteins;  and  a  non-saturable  renal  clearance  pathway.  The
alf-life  of  UFH  is  90-120  min  depending  on  the  clearance
echanism.  The  existence  of  these  two  clearance  mecha-
isms  can  lead  to  intra-  and  inter-individual  variability  in  the
harmacodynamic  effects  of  UFH,  which  is  a  limitation  on  its
se  due  to  the  unpredictability  of  its  anticoagulant  effects,
hich  necessitate  monitoring  by  measurement  of  activated
artial  thromboplastin  time  or  activated  clotting  time.
Although  there  have  been  no  placebo-controlled  trials,
he  value  of  UFH  was  highlighted  by  the  OASIS-6  trial  on  fon-
aparinux,  in  which  UFH  was  administered  to  some  of  the
ontrol  group.36 In  the  subgroup  of  patients  with  STEMI  who
nderwent  primary  PCI,  UFH  reduced  the  risk  of  thrombotic
ailout  or  catheter  thrombosis,  none  of  the  latter  occur-
ing  with  UFH.  There  was  also  a  trend  towards  an  increased
isk  of  death  or  reinfarction  in  primary  PCI  patients  treated
ith  fondaparinux  compared  to  UFH  at  30  days  and  90-180
ays,  with  a  signiﬁcant  subgroup  interaction  (primary  PCI  vs.
on-primary  PCI,  trending  for  a  favorable  effect  of  UFH  in
he  primary  PCI  subgroup,  and  a  signiﬁcant  favorable  effect
f  fondaparinux  in  the  non-primary  PCI  subgroup).36 For
hese  reasons  fondaparinux  is  not  recommended  for  patients
ith  STEMI  undergoing  PCI,  but  is  a valid  anticoagulant  for
TEMI  patients  treated  with  ﬁbrinolysis.3 UFH  is  an  option
or  parenteral  anticoagulants  in  this  setting  according  to  the
uropean  Society  of  Cardiology  (ESC)  guidelines.1
Regarding  dosage  of  UFH,  the  initial  bolus  should  be
eight-adjusted,  and  should  be  as  follows  according  to
xpectation  of  the  use  of  GP  IIb/IIIa  inhibitors:  UFH  70-100
U/kg  when  no  GP  IIb/IIIa  inhibitor  is  planned,  or  UFH  50-60
U/kg  when  the  use  of  GP  IIb/IIIa  inhibitors  is  expected.1
The  main  safety  issues  are  bleeding  events  and  throm-
ocytopenia.  For  bleeding  events,  protamine  can  be
dministered  to  reverse  the  anticoagulant  effect  of  UFH.
he  incidence  of  heparin-induced  thrombocytopenia  (HIT)
anges  from  0.1%  to  5.0%  and  at  least  one  quarter  of
hese  patients  develop  thrombotic  complications.  In  HIT,  the
latelet  count  fall  is  50%  or  more  and  the  nadir  is  above
0×109/l.37 It  usually  occurs  after  5-10  days  of  exposure
o  UFH  or  sooner  if  the  patient  was  exposed  in  the  previ-
us  30  days.37 Both  HIT  and  HIT-related  thrombotic  events
re  related  to  the  development  of  immunoglobulins  against
omplexes  of  platelet  factor  4  and  UFH.37
ow  molecular  weight  heparins
ow  molecular  weight  heparins  (LMWH)  are  small  antithrom-
in  polysaccharides  derived  from  UFH.  LMWH  have  more
nti-Xa  than  anti-IIa  activity  and  enhance  the  release  of
issue  factor  pathway  inhibitors.  These  drugs  do  not  bind
o  endothelial  cells  or  macrophages,  and  hence  have  a
redictable  dose-effect  relationship  using  bolus  administra-
ions.  Their  bioavailability  is  also  higher,  enabling  effective
ubcutaneous  administration.  Regarding  safety  issues,  the
ate  of  HIT  is  lower  with  LMWH  than  with  UFH,  but  in
leeding  conditions  the  antidote  protamine  is  less  effec-
ive,  since  it  only  partially  neutralizes  the  anti-Xa  effect
f  LMWH.  The  new  anti-factor  Xa  antidote  andexanet  alfa
ay  be  used  to  reverse  enoxaparin’s  anticoagulant  effect  in
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Study
ATOLL (1)
HORIZONS-AMI (2)
MATRIX (STEMI subgroup) (3)
VALIDATE-SWEDEHEART (STEMI subgroup) (4)
(1) Enoxaparin vs. UFH; death, MI, PCI failure, or major bleeding
(2) Bivalirudin vs. UFH+iGP IIb/IIIa] major bleeding (co-primary outcome)
(3) Bivalirudin vs. UFH; major bleeding (secondary outcome)
(4) Bivalirudin vs. UFH; death, MI, or major bleeding
Estimate (RR/OR/HR) Estimate (RR/OR/HR)
95% CI
0.83 [0.68, 1.01]
0.60 [0.46, 0.77]
0.60 [0.39, 0.92]
0.95 [0.78, 1.17]
0.5 0.7 1 1.5 2
Favors intervention Favors control
95% CI
Figure  2  Results  of  selected  trials  assessing  anticoagulant  agents  in  patients  with  ST-segment  elevation  myocardial  infarction.
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cI: conﬁdence  interval;  CV:  cardiovascular;  GP:  glycoprotein;
ercutaneous coronary  intervention;  RR:  relative  risk;  STEMI:
eparin.
atients  requiring  rapid  hemostasis.38 However,  the  Andex-
net  Alfa,  a  Novel  Antidote  to  the  Anticoagulation  Effects  of
XA  Inhibitors  4  (ANNEXA-4)  trial  only  enrolled  four  patients
ith  major  bleeding  treated  with  enoxaparin  (out  of
7  patients  treated  with  factor  Xa  inhibitors).38
The  main  clinical  evidence  for  the  use  of  LMWH  in  STEMI
atients  derives  from  the  Acute  STEMI  Treated  with  pri-
ary  angioplasty  and  intravenous  enoxaparin  Or  UFH  to
ower  ischemic  and  bleeding  events  at  short-  and  Long-term
ollow-up  study  (ATOLL).39 Compared  to  UFH,  enoxaparin
intravenous  bolus  of  0.5  mg/kg  followed  by  subcutaneous
njections  every  12  hours)  did  not  signiﬁcantly  (p=0.06)
educe  the  primary  composite  outcome  of  death,  compli-
ation  of  MI,  procedure  failure,  or  major  bleeding  in  910
TEMI  patients  (Figure  2).  However,  secondary  outcomes
ncluding  death,  recurrent  acute  coronary  syndrome,  and
rgent  revascularization  were  signiﬁcantly  decreased  (41%
RR)  with  enoxaparin.39 No  differences  were  observed  in
ajor  bleeding.  Based  on  these  ﬁndings,  the  ESC  guidelines
tate  that  LMWH  may  be  considered  instead  of  UFH  (class  IIb
ecommendation).1 Another  advantage  of  LWMH  over  UFH  is
he  lower  risk  of  HIT.
ivalirudin
ivalirudin  is  a  polypeptide  that  is  a  direct  thrombin
nhibitor,  binding  both  circulating  and  clot-bound  thrombin.
The  Harmonizing  Outcomes  With  Revascularization  and
tents  in  Acute  Myocardial  Infarction  (HORIZONS-AMI)
rial  compared  UFH  plus  a  GP  IIb/IIIa  inhibitor  with
ivalirudin  alone  (0.75  mg/kg  intravenous  bolus  followed  by
.75  mg/kg/hour  infusion)  in  patients  undergoing  primary
CI.40
In  3602  STEMI  patients  undergoing  primary  PCI,
ivalirudin,  compared  to  UFH  plus  GP  IIb/IIIa  inhibitors  (52%
bciximab,  46%  tiroﬁban),  showed  an  RRR  of  24%  within  30
ays  in  net  adverse  clinical  events,  a  composite  of  cardio-
ascular  death,  MI,  target  vessel  revascularization,  stroke  or
ajor  bleeding,  mostly  due  to  the  40%  RRR  in  major  bleed-
ng  (Figure  2).40 An  increased  risk  of  stent  thrombosis  within
4  hours  was  observed  in  the  bivalirudin  group.
The  European  Ambulance  Acute  Coronary  Syndrome
ngiography  (EUROMAX)  trial  studied  2218  STEMI  patients
ransported  for  primary  PCI  and  randomized  to  bivalirudin
T
d
p
ohazard  ratio;  MI:  myocardial  infarction;  OR:  odds  ratio;  PCI:
egment  elevation  myocardial  infarction;  UFH:  unfractionated
bolus  and  infusion  for  at  least  four  hours  after  PCI  at
.25  mg/kg/hour)  or  UFH  (and  optional  use  of  GP  IIb/IIIa
nhibitors).41 The  primary  outcome  of  death  and  major
leeding  was  signiﬁcantly  decreased,  due  to  the  57%  RRR  in
ajor  bleeding.41 Similarly  to  the  HORIZONS-AMI  trial,  the
isk  of  acute  stent  thrombosis  was  signiﬁcantly  higher.
The  Minimizing  Adverse  Hemorrhagic  Events  by  Transra-
ial  Access  Site  and  Systemic  Implementation  of  Angiox
MATRIX)  trial  also  compared  bivalirudin  with  UFH  (with
P  IIb/IIIa  inhibitors  only  in  bail-out  circumstances).42 This
rial  included  7213  ACS  patients,  4010  (56%)  with  STEMI.
he  results  for  the  STEMI  group  were  not  different  from
he  overall  study  results.43 The  risk  of  death,  non-fatal
I  and  non-fatal  stroke  was  similar  between  groups,  but
here  was  a signiﬁcant  40%  RRR  in  major  bleeding  with
ivalirudin  in  the  STEMI  group  (Figure  2).  The  MATRIX  study
lso  assessed  the  potential  impact  of  post-PCI  bivalirudin
nfusion;  this  strategy  did  not  improve  any  outcome,  includ-
ng  stent  thrombosis.42
The  Bivalirudin  versus  Heparin  in  ST-Segment  and  Non-
T-Segment  Elevation  Myocardial  Infarction  in  Patients  on
odern  Antiplatelet  Therapy  in  the  Swedish  Web  System
or  Enhancement  and  Development  of  Evidence-based  Care
n  Heart  Disease  Evaluated  according  to  Recommended
herapies  Registry  Trial  (VALIDATE-SWEDEHEART)  was  a  ran-
omized  open-label  registry-based  controlled  clinical  trial
hat  compared  bivalirudin  and  UFH  monotherapy  in  6006
atients  with  MI  (3001  with  STEMI).  The  clinical  impact  of
ivalirudin  was  similar  to  UFH  in  monotherapy  in  the  over-
ll  cohort  as  well  as  in  the  STEMI  subgroup  in  terms  of
he  composite  primary  endpoint  of  all-cause  mortality,  MI
r  major  bleeding  during  180  days  of  follow-up  (Figure  2).
o  signiﬁcant  differences  were  observed  in  any  of  the  sec-
ndary  endpoints.
iscussion
TEMI  is  an  acute  thrombus-driven  event.  The  importance
f  this  pathophysiological  link  is  highlighted  in  this  review,
n  which  the  main  pharmacokinetic,  pharmacodynamic  and
linical  data  on  antithrombotic  drugs  in  STEMI  are  reviewed.
hese  adjuvant  medical  agents,  particularly  antiplatelet
rugs,  have  signiﬁcantly  improved  the  prognosis  of  this
atient  group.  After  aspirin  (with  ISIS-2),6 the  breakthrough
f  P2Y12 inhibitors  with  ticlopidine  marked  a  historic  step.
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Table  1  2017  European  Society  of  Cardiology  recommendations  for  antithrombotic  therapy  in  patients  with  ST-elevation
myocardial  infarction  undergoing  primary  percutaneous  intervention.3
Class  of
recommendation
(wording)
I
(Is  recommended)
IIa
(Should  be
considered)
IIb
(May  be
considered)
III
(Is  not
recommended)
Antiplatelet  agents  Oral  or  IV  aspirin
P2Y12 inhibitor  in  addition  to
aspirin
Ticagrelor
Prasugrel  (clopidogrel-naïve
patients  aged  <75  years;  no
history  of  stroke  or  TIA)
Clopidogrel  when  ticagrelor  or
prasugrel  are  unavailable  or
contraindicated
GP  IIb/IIIa
inhibitors  as
bailout  therapy  in
patients  with  high
thrombotic
burden,  slow  ﬂow
or no-reﬂow
GP  IIb/IIIa
inhibitors  as
upstream  therapy
in  high-risk
patients
transferred  for
primary  PCI
Routine  use  of  GP
IIb/IIIa  inhibitors
in addition  to  UFH
in primary  PCI
-
Anticoagulant  agents  Bivalirudin  over  routine  UFH  with
GP IIb/IIIa  inhibitors
UFH  in  primary  PCI  patients  not
receiving  bivalirudin  or  enoxaparin
-  Enoxaparin  over
UFH
Fondaparinux  in
primary  PCI
patients
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-GP: glycoprotein; IV: intravenous; PCI: percutaneous coronary inte
In  the  STARS  trial  the  combination  of  ticlopidine  and  aspirin
in  stented  patients  (patients  with  recent  MI  were  excluded)
showed  a  decrease  in  stent  thrombosis-related  events  com-
pared  to  aspirin  alone  and  aspirin  combined  with  warfarin.44
In  the  ISAR  trial  the  combination  of  aspirin  and  ticlopi-
dine  (24%  of  the  patients  in  this  group  had  had  acute  MI)
was  superior  to  aspirin  with  phenprocoumon  (a  vitamin  K
antagonist).45 The  former  reduced  the  composite  endpoint
of  cardiovascular  mortality,  non-fatal  MI  or  revasculariza-
tion,  as  well  as  thrombotic  stent  occlusion.45 Consequently,
the  advent  of  GP  IIb/IIIa  inhibitors  contributed  signiﬁcantly
to  the  perception  that  dual  antiplatelet  therapy  was  nec-
essary  in  acute  coronary  syndromes.  The  process  of  PCI,
including  intervention  in  STEMI  and  the  evolution  to  drug-
eluting  stents  and  radial  access,  and  inhibition  of  the  P2Y12
receptor  pathway  with  clopidogrel,  prasugrel  and  ticagrelor,
have  since  been  further  studied  and  optimized.  Nowadays
the  mainstay  for  antiplatelet  therapy  in  STEMI  is  aspirin  and
a  potent  P2Y12 inhibitor  (usually  ticagrelor  or  prasugrel).  GP
IIb/IIIa  inhibitors  are  reserved  for  bailout  situations,  while
cangrelor  may  play  a  role  due  to  its  rapid  antiplatelet  action
in  cases  where  the  pharmacodynamic  effects  of  the  newer
and  faster  P2Y12 inhibitors  are  not  optimal.  In  STEMI,  the
ﬁbrin-rich  thrombi  that  occlude  arteries  are  the  result  of
platelet  activation  and  also  of  the  release  of  tissue  factor
by  the  damaged  vessel  that  leads  to  activation,  ampliﬁcation
and  propagation  of  the  coagulation  cascade.  Anticoagulants
in  this  setting  are  given  to  prevent  expansion  and  enhance-
ment  of  thrombi.  Furthermore,  contemporary  management
with  primary  PCI  requires  a  suitable  antithrombotic  envi-
ronment  to  prevent  catheter  thrombosis,  which  may  be
achieved  with  UFH,  enoxaparin  or  bivalirudin.  Fondaparinux
was  found  to  decrease  the  risk  of  death  or  MI,  particu-
larly  in  patients  managed  medically  or  in  those  receiving
ﬁbrinolysis  (mostly  streptokinase).  In  patients  undergoing
primary  PCI,  fondaparinux  increased  the  risk  of  catheter
thrombosis  and  no  clinical  beneﬁt  was  noted  regarding
-
-ion; TIA: transient ischemic attack; UFH: unfractionated heparin.
ther  outcomes.  Fondaparinux  is  therefore  contraindicated
n  patients  undergoing  primary  PCI.  Regarding  the  other
nticoagulants,  UFH  remains  the  gold  standard  intravenous
nticoagulant,  although  its  anti-ischemic  efﬁcacy  was  chal-
enged  by  enoxaparin  in  one  trial  (ATOLL39),  and  despite
oncerns  of  increased  risk  of  stent  thrombosis  the  major
leeding  risk  was  shown  to  be  lower  with  bivalirudin.
he  2017  European  Society  of  Cardiology
ecommendations  for  antithrombotic  therapy  in
atients  with  ST-elevation  myocardial  infarction
ndergoing  primary  percutaneous  intervention3
ntiplatelet  drugs
 Aspirin  is  recommended  (class  I).
 A  P2Y12 inhibitor  is  recommended  in  addition  to  aspirin
(class  I),  particularly  ticagrelor  (class  I)  or  prasugrel  (in
clopidogrel-naïve  patients  aged  <75  years  or  with  no  his-
tory  of  stroke  or  transient  ischemic  attack  --  class  I).
 GP  IIb/IIIa  inhibitors  should  be  considered  for  bailout
therapy  in  patients  with  high  thrombotic  burden  or
complications,  including  slow  ﬂow  or  no-reﬂow  (class  IIa).
 GP  IIb/IIIa  inhibitors  may  be  considered  for  upstream  ther-
apy  in  high-risk  patients  undergoing  transfer  for  primary
PCI  (class  IIb),  or  as  routine  adjunct  antiplatelet  therapy
in  patients  treated  with  UFH  (class  IIb).
nticoagulant  drugs
 Bivalirudin  is  recommended  over  routine  UFH  with  GP
IIb/IIIa  inhibitors  (class  I).
 Enoxaparin  may  be  preferred  to  UFH  (class  IIa).
 UFH  should  be  used  in  STEMI  patients  undergoing  primary
PCI  not  receiving  bivalirudin  or  enoxaparin  (class  I).
 Fondaparinux  is  contraindicated  in  STEMI  patients  under-
going  primary  PCI  (class  III).
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Table  1  summarizes  the  recommendations  and  their
lasses  regarding  antithrombotic  therapy  in  patients  with
TEMI  treated  with  primary  PCI.
onclusions
dvances  in  antithrombotic  treatment  have  led  to  signiﬁ-
ant  improvements  in  the  prognosis  of  patients  with  STEMI
reated  by  primary  PCI.  The  growing  body  of  evidence  on
ach  of  these  therapeutic  options  poses  new  challenges  in
erms  of  drug  combinations.
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